Merck and Moderna maintain a long-standing collaboration agreement on their personalized mRNA cancer vaccine (intismeran autogene) in combination with Keytruda, most recently strengthened by positive Phase 3 interim melanoma data released on August 19, 2026, which drove sharp gains in Moderna shares. This structure allows joint development, cost-sharing, and commercialization without necessitating a full merger or acquisition, aligning with Merck’s strategy of pursuing targeted oncology bolt-ons and internal pipeline expansion to offset Keytruda exclusivity loss. With no disclosed talks, regulatory filings, or strategic reviews signaling a change in control, and historical precedent of equity divestitures rather than consolidation, trader consensus prices the probability of an announced deal in 2026 at just 19%. Key upcoming catalysts include further Phase 3 readouts and potential approval pathways that could reinforce the partnership model.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateMerck & Moderna merger/acquisition announced in 2026?
Merck & Moderna merger/acquisition announced in 2026?
3% tsansa
BAGO
BAGO
Dec 31, 2026
3% tsansa
BAGO
BAGO
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a long-standing collaboration agreement on their personalized mRNA cancer vaccine (intismeran autogene) in combination with Keytruda, most recently strengthened by positive Phase 3 interim melanoma data released on August 19, 2026, which drove sharp gains in Moderna shares. This structure allows joint development, cost-sharing, and commercialization without necessitating a full merger or acquisition, aligning with Merck’s strategy of pursuing targeted oncology bolt-ons and internal pipeline expansion to offset Keytruda exclusivity loss. With no disclosed talks, regulatory filings, or strategic reviews signaling a change in control, and historical precedent of equity divestitures rather than consolidation, trader consensus prices the probability of an announced deal in 2026 at just 19%. Key upcoming catalysts include further Phase 3 readouts and potential approval pathways that could reinforce the partnership model.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Binuksan ang Market: Aug 19, 2026, 3:58 PM ET
Volume
$351Petsa ng Pagtatapos
Dec 31, 2026Binuksan ang Market
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a long-standing collaboration agreement on their personalized mRNA cancer vaccine (intismeran autogene) in combination with Keytruda, most recently strengthened by positive Phase 3 interim melanoma data released on August 19, 2026, which drove sharp gains in Moderna shares. This structure allows joint development, cost-sharing, and commercialization without necessitating a full merger or acquisition, aligning with Merck’s strategy of pursuing targeted oncology bolt-ons and internal pipeline expansion to offset Keytruda exclusivity loss. With no disclosed talks, regulatory filings, or strategic reviews signaling a change in control, and historical precedent of equity divestitures rather than consolidation, trader consensus prices the probability of an announced deal in 2026 at just 19%. Key upcoming catalysts include further Phase 3 readouts and potential approval pathways that could reinforce the partnership model.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$351Petsa ng Pagtatapos
Dec 31, 2026Binuksan ang Market
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna maintain a long-standing collaboration agreement on their personalized mRNA cancer vaccine (intismeran autogene) in combination with Keytruda, most recently strengthened by positive Phase 3 interim melanoma data released on August 19, 2026, which drove sharp gains in Moderna shares. This structure allows joint development, cost-sharing, and commercialization without necessitating a full merger or acquisition, aligning with Merck’s strategy of pursuing targeted oncology bolt-ons and internal pipeline expansion to offset Keytruda exclusivity loss. With no disclosed talks, regulatory filings, or strategic reviews signaling a change in control, and historical precedent of equity divestitures rather than consolidation, trader consensus prices the probability of an announced deal in 2026 at just 19%. Key upcoming catalysts include further Phase 3 readouts and potential approval pathways that could reinforce the partnership model.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong